1492 Capital Management’s Acorda Therapeutics ACOR Stock Holding History

1492 Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-822	Closed	-$4.22M	–	120
2015 Q4	$4.22M	Sell	822 -18	-2%	-$78.7K	3.07%	7
2015 Q3	$2.67M	Buy	840 +43	+5%	+$167K	1.9%	16
2015 Q2	$3.19M	Sell	797 -50	-6%	-$193K	2.02%	16
2015 Q1	$3.38M	Buy	847 +92	+12%	+$421K	1.96%	19
2014 Q4	$3.7M	Sell	755 -112	-13%	-$481K	2.32%	12
2014 Q3	$3.52M	Buy	867 +44	+5%	+$165K	1.95%	18
2014 Q2	$3.33M	Sell	823 -8	-1%	-$32.6K	1.71%	21
2014 Q1	$3.78M	Buy	+831	New	+$3.36M	1.88%	20

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

1492 Capital Management's ACOR Position: Q1 2016 in Review

1492 Capital Management sold out of Acorda Therapeutics (ACOR) in Q1 2016, closing a stake of 822 shares — an estimated $4.22M sold.

1492 Capital Management first reported a position in ACOR in Q1 2014 and held it in 8 quarters. The position peaked at $4.22M in Q4 2015. 194 funds tracked by Wall St. Rank hold ACOR as of Q1 2016.

1492 Capital Management reported no remaining Acorda Therapeutics position as of Q1 2016 after selling out during the quarter.
1492 Capital Management sold 822 Acorda Therapeutics shares in Q1 2016, an estimated $4.22M.
1492 Capital Management first reported a position in Acorda Therapeutics in Q1 2014 and held it in 8 quarters.
1492 Capital Management's Acorda Therapeutics position peaked at $4.22M in Q4 2015.
194 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2016.

Based on 1492 Capital Management's 13F filing for Q1 2016, filed 11 May 2016.